^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    YES1 amplification

    i
    Other names: YES1, YES Proto-Oncogene 1, Src Family Tyrosine Kinase, V-Yes-1 Yamaguchi Sarcoma Viral Oncogene Homolog 1, Tyrosine-Protein Kinase Yes, Proto-Oncogene C-Yes, YES1 Proto-Oncogene, Src Family Tyrosine Kinase, Proto-Oncogene Tyrosine-Protein Kinase YES, Yamaguchi Sarcoma Oncogene, Cellular Yes-1 Protein, P61-YES, P61-Yes, HsT441, C-Yes
    Entrez ID:
    7525
    Related biomarkers:
    Expression
    CNA
    Others
    1year
    Role of YES1 signaling in tumor therapy resistance. (PubMed, Cancer Innov)
    Moreover, recent advances in targeted therapy for YES1-amplified malignancies are summarized. Finally, we conclude that targeting YES1 may reverse drug resistance and serve as a valuable tumor treatment strategy.
    Review • Journal
    |
    YES1 (YES Proto-Oncogene 1, Src Family Tyrosine Kinase)
    |
    YES1 amplification
    over2years
    SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors. (PubMed, JCO Precis Oncol)
    Our results demonstrate the therapeutic potential of SFK inhibition in primary tumorigenesis and AR driven by YES1/YAP1 signaling.
    Preclinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • YAP1 (Yes associated protein 1) • YES1 (YES Proto-Oncogene 1, Src Family Tyrosine Kinase)
    |
    EGFR mutation • ALK positive • ALK fusion • ALK mutation • YES1 amplification • YAP1 overexpression • YES1 overexpression
    |
    MSK-IMPACT
    almost3years
    YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development. (PubMed, Int J Mol Sci)
    YES1 amplification was further enhanced after acquired resistance to T-DM1 became apparent, and the knockdown of the YES1 or the administration of the Src inhibitor dasatinib restored sensitivity to T-DM1. Our results indicate that YES1 is also strongly associated with T-DM1 resistance after the development of acquired resistance to trastuzumab, and the continuous inhibition of YES1 is important for overcoming resistance to T-DM1.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification • YES1 amplification
    |
    dasatinib • Kadcyla (ado-trastuzumab emtansine)